Overview

Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders

Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to examine the effect of standard dosing of cyproheptadine for both cycled and continuous administration, as compared to no medication, on appetite stimulation and growth in the pediatric gastroenterology feeding team patient population. The secondary aim is to evaluate the effect, if any, of the suspected tachyphylaxis that is commonly associated with cyproheptadine use. The third aim will be to examine the type and duration of side effects of cyproheptadine in this population. The ultimate goal will be to create a standardized protocol for cyproheptadine therapy in children with feeding disorders and suboptimal growth.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Cyproheptadine
Criteria
Inclusion Criteria:

- All children aged 1-10 years, presenting to initial intake appointment with the
Pediatric Gastroenterology Feeding Team Clinic at the Children's Hospital of Wisconsin
(CHW), with BMI Z score of < or equal to 0 (normal WHO BMI defined as Z score of -1 to
1), who have a parent willing to participate, will qualify for inclusion in the study.
Children with vomiting due to presumed volume intolerance may be included in the
study.

Exclusion Criteria:

- Untreated organic disease Anatomical barrier to swallowing or known swallowing
disorder Diagnosis of severe developmental delay or mental retardation Significant
brain pathology or seizure disorder that may affect oropharyngeal motor skills On
medication with known effects on appetite or interactions with cyproheptadine